title: Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation.
abstract: Currently there is minimal concern that islet allograft failure could result from the development of anti-human leukocyte antigen (HLA) antibodies reactive to the allograft. We report here a case of islet allograft failure where the recipient developed immunoglobulin G anti-HLA class I antibodies reactive to HLA antigens present in two of the three islet cell donors. The patient had no detectable anti-HLA antibodies prior to the transplant but these antibodies were detected approximately 4 months posttransplant. Of concern, these antibodies developed despite induction with anti-IL2R antibodies (Zenapex) prior to intraportal islet cell infusion, low-dose tacrolimus (12-hour troughs 3 to 5 ng/mL) and rapammune (target troughs 12 to 15 ng/mL). The patient was not presensitized with blood products or a previous allograft. Her husband, however, shared antigens present in one of the islet donors and the recipient could have been presensitized to her husband during her two pregnancies. This case clearly demonstrates that islet allografts can lead to development of anti-HLA antibodies, which can cause islet allograft failure, as is the case with solid organ transplants, and hence emphasizes the need to monitor for such antibodies pre- and posttransplant. Additionally it appears that currently recommended immunosuppression may not be sufficient to inhibit a humoral response to both alloantigens and autoantigens.
authors.affiliation: Department of Internal Medicine and Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA. pil@virginia.edu
authors.forename: P I
authors.initials: PI
authors.lastname: Lobo
authors.forename: C
authors.initials: C
authors.lastname: Spencer
authors.forename: W D
authors.initials: WD
authors.lastname: Simmons
authors.forename: K D
authors.initials: KD
authors.lastname: Hagspiel
authors.forename: J F
authors.initials: JF
authors.lastname: Angle
authors.forename: S
authors.initials: S
authors.lastname: Deng
authors.forename: J
authors.initials: J
authors.lastname: Markmann
authors.forename: A
authors.initials: A
authors.lastname: Naji
authors.forename: S E
authors.initials: SE
authors.lastname: Kirk
authors.forename: T
authors.initials: T
authors.lastname: Pruett
authors.forename: K L
authors.initials: KL
authors.lastname: Brayman
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous; D017211:Treatment Failure
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015395:Histocompatibility Antigens Class I; D007328:Insulin